Skip to main content
Journal cover image

Retrospective analysis of the efficacy and safety of neoadjuvant gemcitabine and cisplatin in muscle-invasive bladder cancer.

Publication ,  Journal Article
Meleis, L; Moore, R; Inman, BA; Harrison, MR
Published in: J Oncol Pharm Pract
March 2020

BACKGROUND: Neoadjuvant cisplatin-based combination chemotherapy for muscle-invasive bladder cancer (MIBC) improves overall and disease-free survival. However, there is much debate over the optimal neoadjuvant regimen. Gemcitabine plus cisplatin (GC) has been the neoadjuvant regimen of choice for many institutions for patients with MIBC based on data extrapolated from the metastatic setting. Based on recent data, many institutions are transitioning to variations of methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) as the neoadjuvant regimen of choice. OBJECTIVE: To assess the effectiveness and safety of neoadjuvant chemotherapy with gemcitabine plus cisplatin in patients with muscle-invasive bladder cancer prior to cystectomy. METHODS: This is a single-center, retrospective, cohort study at Duke University Hospital (DUH). Patients included had MIBC and received gemcitabine plus cisplatin chemotherapy prior to a cystectomy. The primary endpoint was to assess the pathologic complete response (pCR) rate in MIBC after treatment with gemcitabine and cisplatin. Patients were split into two groups, those who received their chemotherapy at DUH, and those who received their chemotherapy at an outside facility. RESULTS: Overall pCR rate for all patients (n = 36) was 14%. The pCR rates for patients in the Duke Chemotherapy Group (n = 17) and in the Community Chemotherapy Group (n = 19) were 24% and 5%, respectively. GC was overall well tolerated in most patients with few adverse events ≥ grade 3. CONCLUSIONS: This retrospective study demonstrates a consistent pCR rate (24% in Duke Chemotherapy Group) for neoadjuvant GC in MIBC compared with other literature. The overall pCR rate for all patients was 14%.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

J Oncol Pharm Pract

DOI

EISSN

1477-092X

Publication Date

March 2020

Volume

26

Issue

2

Start / End Page

330 / 337

Location

England

Related Subject Headings

  • Urinary Bladder Neoplasms
  • Treatment Outcome
  • Retrospective Studies
  • Oncology & Carcinogenesis
  • Neoplasm Invasiveness
  • Neoadjuvant Therapy
  • Muscle Neoplasms
  • Middle Aged
  • Male
  • Humans
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Meleis, L., Moore, R., Inman, B. A., & Harrison, M. R. (2020). Retrospective analysis of the efficacy and safety of neoadjuvant gemcitabine and cisplatin in muscle-invasive bladder cancer. J Oncol Pharm Pract, 26(2), 330–337. https://doi.org/10.1177/1078155219845434
Meleis, Laura, Russell Moore, Brant A. Inman, and Michael R. Harrison. “Retrospective analysis of the efficacy and safety of neoadjuvant gemcitabine and cisplatin in muscle-invasive bladder cancer.J Oncol Pharm Pract 26, no. 2 (March 2020): 330–37. https://doi.org/10.1177/1078155219845434.
Meleis L, Moore R, Inman BA, Harrison MR. Retrospective analysis of the efficacy and safety of neoadjuvant gemcitabine and cisplatin in muscle-invasive bladder cancer. J Oncol Pharm Pract. 2020 Mar;26(2):330–7.
Meleis, Laura, et al. “Retrospective analysis of the efficacy and safety of neoadjuvant gemcitabine and cisplatin in muscle-invasive bladder cancer.J Oncol Pharm Pract, vol. 26, no. 2, Mar. 2020, pp. 330–37. Pubmed, doi:10.1177/1078155219845434.
Meleis L, Moore R, Inman BA, Harrison MR. Retrospective analysis of the efficacy and safety of neoadjuvant gemcitabine and cisplatin in muscle-invasive bladder cancer. J Oncol Pharm Pract. 2020 Mar;26(2):330–337.
Journal cover image

Published In

J Oncol Pharm Pract

DOI

EISSN

1477-092X

Publication Date

March 2020

Volume

26

Issue

2

Start / End Page

330 / 337

Location

England

Related Subject Headings

  • Urinary Bladder Neoplasms
  • Treatment Outcome
  • Retrospective Studies
  • Oncology & Carcinogenesis
  • Neoplasm Invasiveness
  • Neoadjuvant Therapy
  • Muscle Neoplasms
  • Middle Aged
  • Male
  • Humans